Twitter | Search | |
This is the legacy version of twitter.com. We will be shutting it down on 15 December 2020. Please switch to a supported browser or device. You can see a list of supported browsers in our Help Center.
Michael Chetrit
Cardiologist. AsistProf McGill,Former Advanced Cardiac Imaging Fellow . Interested in Cardiac Amyloid and Pericardial diseases.Views are my own.
951
Tweets
586
Following
518
Followers
Tweets
Michael Chetrit retweeted
Taxiarchis Kourelis Nov 26
Our cardiac plaque proteome paper is out I will outline key findings. We were conservative in defining it and only included proteins increased compared to normal AND disease controls.
Reply Retweet Like
Michael Chetrit Nov 22
Incredible work Amit, though not the least bit surprised. You are an educational force....
Reply Retweet Like
Michael Chetrit retweeted
Allan L. Klein Nov 18
Could be a paradigm shift how we treat recurrent pericarditis
Reply Retweet Like
Michael Chetrit Nov 20
A fantastic event! Highly recommended!
Reply Retweet Like
Michael Chetrit retweeted
JACC Journals Nov 16
Could shear wave become a non-invasive tool for diastolic function assessment after ? Dr. et al. explores in :
Reply Retweet Like
Michael Chetrit retweeted
Ahmad Masri Nov 16
Reply Retweet Like
Michael Chetrit retweeted
Yehia Saleh Nov 14
Reply Retweet Like
Michael Chetrit retweeted
American College of Cardiology Nov 14
Miss day 1 of ? Check out the highlights w/ Drs. & as they look back on the first day's science & featured clinical research, including GALACTIC-HF, AFFIRM-AHF, VITAL-Rhythm, ARREST, TIPS-3, DAPA-CKD & EMPEROR-Reduced. 📽️ here:
Reply Retweet Like
Michael Chetrit Nov 14
Reply Retweet Like
Michael Chetrit Nov 14
Reply Retweet Like
Michael Chetrit retweeted
Dr. Purvi Parwani Nov 14
At ➡️AF +BioProsthetic Mitral Valve, RIVAROXABAN non-inferior to the WARFARIN ➡️ EASIER to use RiVAROXABAN in These Patients!
Reply Retweet Like
Michael Chetrit retweeted
Pishoy Gouda Nov 14
Overall with the use of OCT + CMR, investigators were able to determine the etiology of in 85% of participants!
Reply Retweet Like
Michael Chetrit Nov 14
Reply Retweet Like
Michael Chetrit Nov 13
Reply Retweet Like
Michael Chetrit Nov 13
Reply Retweet Like
Michael Chetrit Nov 10
Reply Retweet Like
Michael Chetrit Nov 10
Reply Retweet Like
Michael Chetrit Nov 6
Reply Retweet Like
Michael Chetrit retweeted
Ahmad Masri Nov 5
We still don't know much about and it is not looking good for (clinical use) in sensitivity 25-30% , false neg 9/12
Reply Retweet Like
Michael Chetrit retweeted
Louise Burrell MD Nov 5
Congrats Jithin on this important letter on COVID-19 and stroke in NY, USA - there is so much more to learn about ACE2 as a risk factor for adverse outcomes - our team in Melbourne is working on this +++
Reply Retweet Like